Adaptation of estrogen-regulated genes in long-term estradiol deprived MCF-7 breast cancer cells

Breast Cancer Research and Treatment

Volumn 94, Issue 3, 2005, Pages 213-223

  Santen, R J ^a   Lobenhofer, E K ^b,c   Afshari, C A ^b,d   Bao, Y ^a   Song, R X ^a  

^a UNIVERSITY OF VIRGINIA HEALTH SYSTEM   (United States)

^b NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES   (United States)

^c Icoria Inc   (United States)

^d AMGEN INC   (United States)

Author keywords

Breast cancer; Cellular adaptation; Estradiol; Estrogen; MCF 7 cells

Indexed keywords

AROMATASE INHIBITOR; COMPLEMENTARY DNA; ESTRADIOL; ESTROGEN; PROTEIN DKFZP; PROTEIN S6; RAP1 PROTEIN; UNCLASSIFIED DRUG;

ADAPTATION; ARTICLE; BREAST CANCER; CANCER CELL; CELL STRAIN MCF 7; CELL TYPE; CONTROLLED STUDY; DNA MICROARRAY; GENE EXPRESSION; GENETIC TRANSFECTION; HUMAN; HUMAN CELL; NUCLEOTIDE SEQUENCE; OVARIECTOMY; PREMENOPAUSE; PRIORITY JOURNAL; REAL TIME POLYMERASE CHAIN REACTION;

ADAPTATION, PHYSIOLOGICAL; AROMATASE INHIBITORS; BREAST NEOPLASMS; DRUG RESISTANCE, NEOPLASM; ESTRADIOL; FEMALE; GENE EXPRESSION PROFILING; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; OLIGONUCLEOTIDE ARRAY SEQUENCE ANALYSIS; OVARIECTOMY; TUMOR CELLS, CULTURED;

EID: 27944468748     PISSN: 01676806     EISSN: None     Source Type: Journal    
DOI: 10.1007/s10549-005-5776-4     Document Type: Article

References (74)

1. Santen RJ: Endocrine-Responsive Cancer. In: Larsen PR, Kronenberg HM, Melmed S, Polonsky KS (eds) Willams Textbook of Endocrinology. Tenth edition, Saunders, Philadelphia, Pennsylania 2003, pp. 1797-1833
2. Masamura S, Santner SJ, Heitjan DF, Santen RJ: Estrogen deprivation causes estradiol hypersensitivity in human breast cancer cells. J Clin Endocrinol Metab 80: 2918-2925, 1995
3. Jeng MH, Shupnik MA, Bender TP, Westin EH, Bandyopadhyay D, Kumar R, Masamura S, Santen RJ: Estrogen receptor expression and function in long-term estrogen-deprived human breast cancer cells. Endocrinology 139: 4164-4174, 1998
4. Jeng MH, Yue W, Eischeid A, Wang JP, Santen RJ: Role of MAP kinase in the enhanced cell proliferation of long term estrogen deprived human breast cancer cells. Breast Cancer Res Treat 62: 167-175, 2000
5. Martin LA, Farmer I, Johnston SR, Ali S, Marshall CJ, Dowsett M: Enhanced ERα, ERBB2 and MAPK signal transduction pathways operate during the adaptation of MCF-7 cells to long term oestradiol deprivation. J Biol Chem 278: 30458-30468, 2003
6. Santen R, Jeng MH, Wang JP, Song R, Masamura S, McPherson R, Santner S, Yue W, Shim WS: Adaptive hypersensitivity to estradiol: potential mechanism for secondary hormonal responses in breast cancer patients. J Steroid Biochem Mol Biol 79: 115-125, 2001
7. Shim WS, Conaway M, Masamura S, Yue W, Wang JP, Kumar R, Santen RJ: Estradiol hypersensitivity and mitogen-activated protein kinase expression in long-term estrogen deprived human breast cancer cells in vivo. Endocrinology 141: 396-405, 2000
8. Chan CM, Martin LA, Johnston SR, Ali S, Dowsett M: Molecular changes associated with the acquisition of oestrogen hypersensitivity in MCF-7 breast cancer cells on long-term oestrogen deprivation. J Steroid Biochem Mol Biol 81: 333-341, 2002
9. Santen RJ, Manni A, Harvey H, Redmond C: Endocrine treatment of breast cancer in women. Endocrine Rev 11: 221-265, 1990
10. Katzenellenbogen BS, Kendra KL, Norman MJ, Berthois Y: Proliferation, hormonal responsiveness, and estrogen receptor content of MCF-7 human breast cancer cells grown in the short-term and long-term absence of estrogens. Cancer Res 47(16): 4355-4360, 1987
11. Yue W, Wang JP, Conaway M, Li Y, Santen RJ. Adaptive hypersensitivity following long-term estrogen deprivation: involvement of multiple signal pathways. J Steroid Biochem Mol Biol 86: 265-274, 2003
12. Murphy LC: Elevated mitogen-activated protein kinase activity in estrogen-nonresponsive human breast cancer cells. Cancer Res 58: 4071-4074, 1998
13. Clarke R, Brunner N, Katzenellenbogen BS, Thompson EW, Norman MJ, Koppi C, Paik S, Lippman ME, Dickson RB: Progression of human breast cancer cells from hormone-dependent to hormone-independent growth both in vitro and in vivo. Proc Natl Acad Sci USA 86: 3649-3653, 1989
14. Herman ME, Katzenellenbogen BS: Alterations in transforming growth factor-alpha and -beta production and cell responsiveness during the progression of MCF-7 human breast cancer cells to estrogen-autonomous growth. Cancer Res 54: 5867-5874, 1994
15. Cho HS, NG PA, Katzenellenbogen BS: Differential regulation of gene expression by estrogen in estrogen growth-independent and dependent MCF-7 human breast cancer cell sublines. Mol Endocrinol 5: 1323-1330, 1991
16. Montano MM, Kraus WL, Katzenellenbogen BS: Identification of a novel transferable cis element in the promoter of an estrogen-responsive gene that modulates sensitivity to hormone and anti-hormone. Mol Endocrinol 11: 330-341, 1997
17. Welshons WV, Jordan VC: Adaptation of estrogen-dependent MCF-7 cells to low estrogen (phenol red-free) culture. Eur J Cancer Clin Oncol 23: 1935-1939, 1987
18. Brunner N, Boulay V, Fojo A, Freter CE, Lippman ME, Clarke R: Acquisition of hormone-independent growth in MCF-7 cells is accompanied by increased expression of estrogen-regulated genes but without detectable DNA amplifications. Cancer Res 53: 283-290, 1993
19. Darbre PD, Daly RJ: Transition of human breast cancer cells from an oestrogen responsive to unresponsive state. J Steroid Biochem Mol Biol 37: 753-763, 1990
20. Daly RJ, Darbre PD: Celluar and molecular events in loss of estrogen sensitivity in ZR-75-1 and T-47-D human breast cancer cells. Cancer Res 50: 5868-5875, 1990
21. Daly RJ, King RJ, Darbre PD: Interaction of growth factors during progression towards steroid independence in T-47-D human breast cancer cells. J Cell Biochem 43: 199-211, 1990
22. Song RX, Mor G, Naftolin F, McPherson RA, Song J, Zhang Z, Yue W, Wang J, Santen RJ: Effect of long-term estrogen deprivation on apoptotic responses of breast cancer cells to 17beta-estradiol. J Natl Cancer Inst 93: 1714-1723, 2001
23. Lobenhofer EK, Bennett L, Cable PL, Li L, Bushel PR, Afshari CA: Regulation of DNA replication fork genes by 17beta-estradiol. Mol Endocrinol 16: 1215-1229, 2002
24. Afshari CA: Perspective: microarray technology, seeing more than spots. Endocrinology 143: 1983-1989, 2002
25. MacLeod MC, Aldaz CM.: Effects of estrogen on global gene expression: identification of novel targets of estrogen action. Cancer Res 60: 5977-5983, 2000
26. Soulez M, Parker MG.: Identification of novel oestrogen receptor target genes in human ZR75-1 breast cancer cells by expression profiling. J Mol Endocrinol 27: 259-274, 2001
27. Chen Y, Dougherty E, Bittner M: Ratio-based decisions and the quantitative analysis of cDNA microarray images. J Biomed Optics 2: 364-374, 1997
28. Bushel PR, Hamadeh H, Bennett L, Sieber S, Martin K, Nuwaysir EF, Johnson K, Reynolds K, Paules RS, Afshari CA., 2001 MAPS: a microarray project system for gene expression experiment information and data validation
29. Ghosh MG, Thompson DA, Weigel RJ: PDZK1 and GREB1 are estrogen-regulated genes expressed in hormone-responsive breast cancer. Cancer Res 60: 6367-6375, 2000
30. Tazawa H, Osman W, Shoji Y, Treuter E, Gustafsson JA, Zilliacus J: Regulation of subnuclear localization is associated with a mechanism for nuclear receptor compression by RIP 140. Mol Cell Biol 23: 4187-4198, 2003
31. Sledge GW. Jr: Vascular endothelial growth factor in breast cancer: biologic and therapeutic aspects. Seminars Oncol 29(3 Suppl 11): 104-10, 2002
32. Ainbinder E, Revach M, Wolstein O, Moshonov S, Diamant N, Dikstein R: Mechanism of rapid transcriptional induction of tumor necrosis factor alpha-responsive genes by NF-kappaB. Mol Cell Biol 22: 6354-62, 2002
33. Gordon GJ, Appasani K, Parcells JP, Mukhopadhyay NK, Jaklitsch MT, Richards WG, Sugarbaker DJ, Bueno R: Inhibitor of apoptosis protein-1 promotes tumor cell survival in mesothelioma. Carcinogenesis 23: 1017-102, 2002
34. Stamenkovic I, Aruffo A, Amiot M, Seed B: The hematopoietic and epithelial forms of CD44 are distinct polypeptides with different adhesion potentials for hyaluronate-bearing cells. EMBO J 10: 343-348, 1991
35. Bergholdt R, Larsen ZM, Andersen NA, Johannesen J, Kristiansen OP, Mandrup-Poulsen T, Nerup J, Pociot F: Danish Study group of IDDM in Childhood. Danish IDDM Epidemiology and Genetics Group.Characterization of new polymorphisms in the 5′ UTR of the human interleukin-1 receptor type 1 gene:linkage to type 1 diabetes and correlation to IL-1R1 plasma level. Genes Immunity 1: 495-5000, 2000
36. Cavet ME, Leboux S, Berk BC: 14-3-3 beta ribosomal S6 kinase (RSK) isoform 1-binding protein that negatively regulates RSK activity. J Biol Chem 278: 18376-18383, 2003
37. Dagar S, Sekosan M, Lee BS, Rubinstein I, Onyuksel H: VIP receptors as molecular targets of breast cancer: implications for targeted imaging and drug delivery. J Controlled Release. 74(1-3): 129-134, 2001
38. Bouschet T, Perez V, Fernandez C, Bockaert J, Eychene A, Journot L: Stimulation of the ERK pathway by GTP-loaded Rap1 requires the concomitant activation of Ras, protein kinase C, and protein kinase A in neuronal cells. J Biol Chem 278: 4778-4785, 2003
39. Transmembrane-4 superfamily proteins associate with activated protein kinase C (PKC) and link PKC to specific beta(1) integrins. J Biol Chem. 276: 25005-25013
40. Asnagli H, Afkarian M, Murphy KM: Cutting edge: identification of an alternative GATA-3 promoter directing tissue-specific gene expression in mouse and human. J Immunol 168: 4268-4271, 2002
41. Shen MR, Wilkins RJ, Chou CY, Ellory JC: Anion exchanger isoform 2 operates in parallel with Na(+)/H(+) exchanger isoform 1 during regulatory volume decrease of human cervical cancer cells. FEBS Lett 512(1-3): 52-58, 2002
42. Vielmetter J, Chen XN, Miskevich F, Lane RP, Yamakawa K, Korenberg JR, Dreyer WJ, 1997 TITLE Molecular characterization of human neogenin, a DCC-related protein, and the mapping of its gene (NEO1) to chromosomal position 15q22.3-q23J Genomics 41: 414-421
43. Mourton T, Hellberg CB, Burden-Gulley SM, Hinman J, Rhee A, Brady Kalnay SM: The PRPmu protein-tyrosine phosphatase binds and recruits the scaffolding protein RACK 1 to cell-cell contacts. J Biol Chem 276: 14896-14901, 2001
44. Schaaf MJ, Cidlowski JA: Molecular mechanisms of glucocorticoid action and resistance. J Steroid Biochem Mol Biol 83: 37-48, 2002
45. Charpentier AH, Bednarek AK, Daniel RL, Hawkins KA, Laflin KJ, Gaddis S, MacLeod MC, Aldaz CM: Effects of estrogen on global gene expression: identification of novel targets of estrogen action. Cancer Res 60: 5977-5983, 2000
46. Jin R, De Smaele E, Zazzeroni F, Nguyen DU, Papa S, Jones J, Cox C, Gelinas C, Franzoso G: Regulation of the gadd45beta promoter by NF-kappaB. DNA Cell Biol 21: 491-503, 2002
47. Cox HM, Tough IR: Neuropeptide Y, Y1, Y2 and Y4 receptors mediate Y agonist responses in isolated human colon mucosa. Br J Pharmacol 135: 1505-1512, 2002
48. Kumar P. Walsh DA: A dual-specificity isoform of the protein kinase inhibitor PKI produced by alternate gene splicing. Biochem J. 362: 533-537, 2002
49. Coulet F, Nadaud S, Agrapart M, Soubrier F: Identification of hypoxia-response element in the human endothelial nitric oxide synthase promoter. J Biol Chem, Sept 8 (Epub ahead of print), 2003
50. Roland J, Murphy BJ, Ahr B, Robert-Hebmann V, Delauzun V, Nye KE, Devaux C, Biard-Piechaczyk M: Role of the intracellular domains of CXCR4 in SDF-1 mediated signaling. Blood 101: 399-406, 2002
51. Guymer RH, McNeil: Analysis of the Arg345Trp disease-associated allele of the EFEMP1 gene in individuals with early onset drusen or familial age-related macular degeneration. Clin Experiment Ophthalmol 30: 419-423, 2002
52. Ouyang B, Li W, Pan H, Meadows J, Hoffmann I, Dai W: The physical association and phosphorylation of Cdc25C protein phosphatase by Prk. Oncogene 18: 6029-6036, 1999
53. Strausberg RL, Feingold EA, Grouse LH, Derge JG: Generation and initial analysis of more than 15,000 full-length human and mouse cDNA sequences. Proc Nat Acad Sci USA 99: 16899-16903, 2002
54. Brott BK, Sokol SY: Regulation of Wnt/LRP signaling by distinct domains of Dickkopf proteins. Mol Cell Biol 22: 6100-6110, 2002
55. Benezra R, de Candia P, Li H, Romero E, Lyden D, Rafii S, Ruzinova M: A genetic approach to understanding tumor angiogenesis. Cold Spring Harbor Symp Quant Biol 67: 249-254, 2002
56. Kushner PJ, Agard DA, Greene GL, Scanlan TS, Shiau AK, Uht RM, Webb P: Estrogen receptor pathways to AP-1. J Steroid Biochem Mol Biol 74: 311-317, 2000
57. Nass SJ, Dickson RB: Defining a role for c-Myc in breast tumorigenesis. Breast Cancer Res Treatment 44: 1-22, 1997
58. Pelengaris S, Khan M, Evan G: c-MYC:more than just a matter of life and death. Nature Rev Cancer 2: 764-776, 2002
59. Carroll JS, Swarbrick A, Musgrove EA, Sutherland RL: Mechanisms of growth arrest by c-myc antisense oligonucleotides in MCF-7 breast cancer cells: implications for the antiproliferative effects of antiestrogens. Cancer Res 62: 3126-3131, 2002
60. Xia H, Mao Q, Paulson HL, Davidson BL: siRNA-mediated gene silencing in vitro and in vivo. Nature Biotechnol : 1006-1010, 1920
61. Czauderna F, Fechtner M, Aygun H, Arnold W, Klippel A, Giese K: Functional studies of the PI(3)-kinase signalling pathway employing synthetic and expressed siRNA. Nucleic Acids Res 31: 670-82, 2003
62. Harris TE, Lawrence JC Jr, TOR Signaling. Science's STKE (212): re15, 2003
63. Martin KA, Blenis J: Coordinate regulation of translation by the PI 3-kinase and mTOR pathways. Adv Cancer Res 86: 1-39, 2002
64. Duronio V, Scheid MP, Ettinger S: Downstream signalling events regulated by phosphatidylinositol 3-kinase activity. Cell Signal 10: 233-239, 1998
65. Hara K, Maruki Y, Long X, Yoshino K, Oshiro N, Hidayat S, Tokunaga C, Avruch J, Yonezawa K: Raptor, a binding partner of target of rapamycin (TOR), mediates TOR action. Cell 110: 177-189, 2002
66. Datta SR, Dudek H, Tao X, Masters S, Fu H, Gotoh Y, Greenberg ME: Akt phosphorylation of BAD couples survival signals to the cell-intrinsic death machinery. Cell 91: 231-241, 1997
67. Waga S, Stillman B: The DNA replication fork in eukaryotic cells. Annu Rev Biochem 67: 721-751, 1998
68. Samudio I, Vyhlidal C, Wang F, Stoner M, Chen I, Kladde M, Barhoumi Burghardt R: Safe S Transcriptional activation of deoxyribonucleic acid polymerase gene expression in MCF-7 cells by 17β-estradiol. Endocrinology 142: 1000-1008, 2001
69. Yue W, Wang JP, Conaway M, Masamura S, Li Y, Santen RJ: Activation of the MAPK pathway enhances sensitivity of MCF-7 breast cancer cells to the mitogenic effect of estradiol. Endocrinology 143: 3221-3229, 2002
70. Ali A, Coombes RC: Endocrine-responsive breast cancer and strategies for combating resistance. Nature Rev Cancer 2: 101-112, 2002
71. Schiff R, Massarweh S, Shou J, Osborne CK: Breast cancer endocrine resistance: how growth factor signaling and estrogen receptor coregulators modulate response. Clin Cancer Res 9: 447S-454S, 2003
72. Bahia H, Ashman JN, Cawkwell L, Lind M, Monson JR, Drew PJ, Greenman J: Karyotypic variation between independently cultured strains of the cell line MCF-7 identified by multicolour fluorescence in situ hybridization. Int J Oncol 20: 489-494, 2002
73. Song R-X, Barnes CJ, Zheng Z, Bao Y, Kumar R, Santen RJ: The role of SHC and insulin like growth factor 1 receptor in mediating the translocation of estrogen receptor alpha to the plasma membrane. Proc Natl Acad Med USA 101: 2076-2081, 2004
74. Hodges LC, Cook JD, Lobenhofer EK, Li L, Bennett L, Bushel PR, Al;daz CXM, Afshari CA, Walker CL: Tamoxifen functions as a molecular agonist inducing cell cycle-associated genes in breast cancer cellsMol Cancer Res 1: 300-311 2003.